In this webinar, Optum will bring together their life sciences consultants, a large payer and pharmaceutical industry experts to share understanding about how patients are managing their medications — and how payers are managing patients — in the ever-changing COVID-19 world.

This panel will discuss:

  • What real-world data (RWD) is telling us about the impact of COVID-19 on patient management and pharmaceutical management
  • What real-time, RWD is telling us about the changing drug landscape such as clinical trials, HEOR, epidemiology and data science
  • How a large payer is managing COVID-19 and its impact on overall medication use
  • The impact of the national COVID-19 shutdown on pharmaceutical use and preventive office visits

Featured Speakers

Mike Anderson, PharmD

Chief Executive Officer, Medicare Part D
UnitedHealthcare

In his current role, Dr. Anderson has overall accountability for Medicare Part D programs within the nation’s largest private Medicare plans, serving nearly ten million beneficiaries with over $35 billion in annual drug expenditures. A pharmacist by training, he has specialized in the care of older adults throughout his career, including work within the Veterans Health Administration and PBM industry. Prior to joining UnitedHealthcare in 2002, Dr. Anderson served on active duty in the U.S. Air Force for over a decade.

Brian D. Bradbury, DSc

Vice President, Center for Observational Research
Amgen, Inc.

As Vice President and Head of the Center for Observational Research (CfOR) at Amgen, Inc., Dr. Bradbury leads a global team of epidemiologists, data scientists, programmers and operations professional who provide strategic and tactical support across the drug development lifecycle. He has authored and co-authored more than 75 peer-reviewed publications in the areas of pharmacoepidemiology, cancer and kidney disease epidemiology and methods for controlling confounding-by-indication in drug safety studies.

Lou Brooks

Vice President, Commercial Analytics, Life Sciences
Optum

For more than 20 years, Brooks has served in a variety of data and analytics roles, all of them focused on developing a better understanding of customer behavior across a number of industries. He has worked in a wide variety of therapeutic categories, including autoimmune, respiratory, and central nervous system disorders, oncology, and cardiovascular conditions.

Kathleen Gondek, PhD

Global Head of Evidence and Outcomes
Takeda

Dr. Gondeck is responsible for developing and implementing global outcomes and epidemiology research strategies to establish the value proposition for Takeda products from early development through commercialization. Prior to joining Takeda she was Vice President, US Medical Science Liaisons and Medical Affairs Operations at Bayer HealthCare pharmaceuticals. Prior to this role Kathleen held a number of positions, of increasing responsibility, within the Health Economics and Outcomes Research (HEOR) function at Bayer during her 15-year career with the organization.

Brian Solow, MD, moderator

Chief Medical Officer, Life Sciences
Optum

Dr. Solow is the CMO of the life sciences segment at Optum which helps pharmaceutical, biotechnology and medical device companies successfully address product development and commercialization challenges. Prior to his current position, Dr. Solow served as the CMO for OptumRx. He is a fellow of the American Academy of Family Physicians, a member of the U.S. Pharmacopeia (USP) Medicare Model Guideline Expert Panel advisory committee, serves on FDA advisory panels, and is the former ISPOR U.S. representative for the International Health Technology Assessment Council.

Date:  Tuesday, June 30, 2020
Time:  1:00pm ET | 10:00am PT
Duration:  60 Minutes

Register now for this webinar